参考文献
[1]Kajio N, Takeshita M, Suzuki K, et al.Anti-centromere antibody target centromere-kinetochore macrocomplex: a comprehensive autoantigen prof iling[J].Annals of the Rheumatic Diseases, 2020.
[2]Fritzler MJ, Rattner JB, Luft LAM, et al.Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins(CENP) and the emerging importance of antibody to CENP—F[J].Autoimmunity reviews, 2011, 10(4): 194—200.
[3]Thongchum R, Nishihara H, Srikulnath K, et al.The CENP—B box, a nucleotide motif involved in centromere formation, has multiple origins in New World monkeys[J].Genes & Genetic Systems, 2020, 94(6): 301—306.
[4]Chik JK, Moiseeva V, Goel PK, et al.Structures of CENP—C cupin domains at regional centromeres reveal unique patterns of dimerization and recruitment functions for the inner pocket[J].Journal of Biological Chemistry, 2019, 294(38): 14119—14134.
[5]Van Den Hoogen F, Khanna D, Fransen J, et al.2013 classif ication criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative[J].Arthritis & Rheumatism, 2013, 65(11): 2737—2747.
[6]Koenig M, Dieudé M, Senécal JL.Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies[J].Autoimmunity reviews, 2008, 7(8): 588—593.
[7]Reveille JD, Solomon DH.Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibody[J].Arthritis Care & Research, 2003, 49(3): 399—412.
[8]Villalta D, Imbastaro T, Di Giovanni S, et al.Diagnostic accuracy and predictive value of extended autoantibody prof ile in systemic sclerosis[J].Autoimmunity reviews, 2012, 12(2): 114—120.
[9]Wielosz E, Dryglewska M, Majdan M.Serological prof ile of patients with systemic sclerosis[J].Postepy Hig Med Dosw (Online), 2014, 68: 987—991.
[10]Liaskos C, Marou E, Simopoulou T, et al.Disease-related autoantibody prof ile in patients with systemic sclerosis[J].Autoimmunity, 2017,50(7): 414—421.
[11]Mierau R, Moinzadeh P, Riemekasten G, et al.Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features[J].Arthritis research & therapy, 2011, 13(5): R172.
[12]Mahler M, You D, Baron M, et al.Anti-centromere antibody in a large cohort of systemic sclerosis patients: comparison between immunof luorescence, CENP—A and CENP—B ELISA[J].Clinica Chimica Acta, 2011, 412(21—22): 1937—1943.
[13]Tsukamoto M, Suzuki K, Takeuchi T.Clinical and immunological features of anti-centromere antibody-positive primary Sjögren’s syndrome[J].Rheumatology and therapy, 2018, 5(2): 499—505.
[14]Gelber AC, Pillemer SR, Baum BJ, et al.Distinct recognition of antibody to centromere proteins in primary Sjögren’s syndrome compared with limited scleroderma[J].Annals of the rheumatic diseases, 2006, 65(8): 1028—1032.
[15]Cavazzana I, Ceribelli A, Taraborelli M, et al.Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis[J].The Journal of rheumatology, 2011, 38(10): 2180—2185.
[16]Chang WS, Schollum J, White DH, et al.A cross-sectional study of autoantibody prof iles in the Waikato systemic sclerosis cohort, New Zealand[J].Clinical rheumatology, 2015, 34(11): 1921—1927.
[17]Vázquez-Abad D, Wallace S, Senécal JL, et al.Anticentromere Autoantibodies[J].Arthritis & Rheumatism: Oき cial Journal of the American College of Rheumatology, 1994, 37(2): 248—252.
[18]Mahler M, Maes L, Blockmans D, et al.Clinical and serological evaluation of a novel CENP—A peptide based ELISA[J].Arthritis research &therapy, 2010, 12(3): R99.
[19]Respaldiza N, Wichmann I, Ocana C, et al.Anti-centromere antibody in patients with systemic lupus erythematosus[J].Scandinavian journal of rheumatology, 2006, 35(4): 290—294.